Ginkgo Bioworks Launches Cost-Effective ADME Profiling Service in US, Offering Competitive Pricing to Beat Chinese or International Vendors.
PorAinvest
jueves, 17 de julio de 2025, 9:05 am ET1 min de lectura
DNA--
The new service promises to accelerate small molecule drug discovery by providing rapid turnaround times and model-ready datasets enriched with structured metadata for AI-powered insights. Ginkgo's automation and scale enable best-in-class pricing and quality, making it an attractive option for the biopharma industry [1].
Key features of the ADME profiling service include:
- Scalable, automated workflows
- Cost-effective pricing with a price match guarantee against international vendors
- Rapid turnaround to keep pace with modern discovery cycles
- Model-ready datasets, enriched with structured metadata for AI-powered insights
Ginkgo Bioworks' commitment to delivering top-tier, cost-effective services is evident in this latest offering. The company aims to empower researchers by providing early access to rich ADME data, enabling them to prioritize candidates and train predictive models more efficiently [1].
This initiative further solidifies Ginkgo's position in the biopharma industry and underscores its dedication to advancing biological engineering through innovative technologies. The service is a testament to Ginkgo's ability to deliver high-quality products and services at competitive prices, making it a valuable asset for researchers and investors alike.
References:
[1] https://www.prnewswire.com/news-releases/ginkgo-bioworks-launches-adme-profiling-service-using-lab-automation-offering-a-us-based-operation-that-will-match-or-beat-pricing-quotes-from-chinese-or-other-international-vendors-302507668.html
Ginkgo Bioworks has launched a cost-effective ADME profiling service using lab automation, aiming to beat or match international vendors' pricing quotes. The service offers high-throughput ADME profiling, rapid turnaround, and model-ready datasets enriched with structured metadata for AI-powered insights. Ginkgo's automation and scale allow for best-in-class pricing and quality, reinforcing its commitment to providing top-tier services to the biopharma industry.
Ginkgo Bioworks (NYSE: DNA), a leading player in synthetic biology, has introduced a new ADME (Absorption, Distribution, Metabolism, and Excretion) profiling service through its subsidiary, Ginkgo Datapoints. This service leverages the company's proprietary RAC automation technology to offer high-throughput ADME profiling at competitive prices, aiming to match or beat quotes from international vendors, including Chinese competitors [1].The new service promises to accelerate small molecule drug discovery by providing rapid turnaround times and model-ready datasets enriched with structured metadata for AI-powered insights. Ginkgo's automation and scale enable best-in-class pricing and quality, making it an attractive option for the biopharma industry [1].
Key features of the ADME profiling service include:
- Scalable, automated workflows
- Cost-effective pricing with a price match guarantee against international vendors
- Rapid turnaround to keep pace with modern discovery cycles
- Model-ready datasets, enriched with structured metadata for AI-powered insights
Ginkgo Bioworks' commitment to delivering top-tier, cost-effective services is evident in this latest offering. The company aims to empower researchers by providing early access to rich ADME data, enabling them to prioritize candidates and train predictive models more efficiently [1].
This initiative further solidifies Ginkgo's position in the biopharma industry and underscores its dedication to advancing biological engineering through innovative technologies. The service is a testament to Ginkgo's ability to deliver high-quality products and services at competitive prices, making it a valuable asset for researchers and investors alike.
References:
[1] https://www.prnewswire.com/news-releases/ginkgo-bioworks-launches-adme-profiling-service-using-lab-automation-offering-a-us-based-operation-that-will-match-or-beat-pricing-quotes-from-chinese-or-other-international-vendors-302507668.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema



Comentarios
Aún no hay comentarios